当前位置: 首页 >> 检索结果
1. Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.
作者: Hiddo J L Heerspink.;José F Cardona.;Shivinder Jolly.;Pablo E Pergola.;Erika de Sousa-Amorim.;Anna L Eriksson.;Martin Fredholm.;Samvel B Gasparyan.;Nicolas J Guzman.;Judith Hartleib-Geschwindner.;Yunyun Jiang.;Maria Leonsson-Zachrisson.;Patrick B Mark.; .
来源: Lancet. 2025年406卷10518期2449-2460页
Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce albuminuria and risk of progression of chronic kidney disease. Non-steroidal mineralocorticoid receptor antagonists (MRA) have similar effects in patients with type 2 diabetes with chronic kidney disease. We aimed to assess efficacy and safety of the novel MRA balcinrenone combined with the SGLT2 inhibitor dapagliflozin in a randomised controlled trial.
2. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
作者: John Deanfield.;A Michael Lincoff.;Steven E Kahn.;Scott S Emerson.;Ildiko Lingvay.;Benjamin M Scirica.;Jorge Plutzky.;Robert F Kushner.;Helen M Colhoun.;G Kees Hovingh.;Signe Stensen.;Peter E Weeke.;Ole Kleist Jeppesen.;Rafael Bravo.;Chau-Chung Wu.;Issei Komuro.;Ferruccio Santini.;Jøran Hjelmesæth.;Miguel Urina-Triana.;Silvio Buscemi.;Donna H Ryan.
来源: Lancet. 2025年406卷10516期2257-2268页
The SELECT trial found semaglutide reduced major adverse cardiovascular events (MACE) in patients with overweight or obesity with cardiovascular disease but without diabetes. We report a prespecified analysis of the SELECT trial on the relationships between baseline adiposity measures, treatment-induced adiposity changes, and subsequent MACE risk.
3. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.
作者: J Randolph Hecht.;Young Suk Park.;Josep Tabernero.;Myung-Ah Lee.;Soohyeon Lee.;Anna C Virgili.;Marc Van den Eynde.;Elisa Fontana.;Marwan Fakih.;Gholamreza Asghari.;Jane So.;Alexander Stein.;Olivier Dubreuil.;Lubomir Bodnar.;Cixin Steven He.;Guan Wang.;Robina Smith.;Cathy Eng.;Anwaar Saeed.; .
来源: Lancet. 2025年406卷10517期2360-2370页
Zanzalintinib is a multitargeted tyrosine-kinase inhibitor that, when combined with atezolizumab, showed promising antitumour activity and manageable toxicity in a phase 1 study. We aimed to compare the efficacy and safety of zanzalintinib-atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer.
4. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
作者: Zheng Wang.;Jia Fan.;Shaolai Zhou.;Yunfan Sun.;Fei Liang.;Yuan Ji.;Fangming Gu.;Tao Li.;Li Peng.;Tao Peng.;Xiaolun Huang.;Zhenbin Ding.;Dousheng Bai.;Bangde Xiang.;Guang Tan.;Tianfu Wen.;Yongyi Zeng.;Feng Han.;Yu Zhang.;Shengdong Wu.;Haitao Zhao.;Yi Chen.;Guoming Shi.;Zhiguo Hou.;Ying Sun.;Wenqing Zhu.;Jian Zhou.
来源: Lancet. 2025年406卷10515期2089-2099页
Surgical resection is the preferred curative approach for patients with early-stage hepatocellular carcinoma, but recurrence remains a major challenge. Consequently, neoadjuvant and adjuvant therapies have been proposed to reduce tumour burden and mitigate the risk of recurrence. The CARES-009 trial aimed to evaluate perioperative camrelizumab plus rivoceranib in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence.
5. Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China.
作者: Yunpeng Yang.;Huaqiang Zhou.;Linquan Tang.;Sufang Qiu.;Yaqian Han.;Dongmei Ji.;Xiaozhong Chen.;Feng Lei.;Song Qu.;Bin Deng.;Lusi Chen.;Jianli Huang.;Ye Guo.;Zhigang Liu.;Dongping Chen.;Jingao Li.;Xiaolei Shu.;Yan Qin.;Zhichao Fu.;Bihui Li.;Peng Zhang.;Shaoqing Chen.;Jinsheng Hong.;Yan Wei.;Xintian Qin.;Shenhong Qu.;Kunyu Yang.;Daren Lin.;Junxian Wang.;Lei Yang.;Sa Xiao.;Hai Zhu.;Yi Zhu.;Li Zhang.; .
来源: Lancet. 2025年406卷10516期2235-2243页
People with recurrent or metastatic nasopharyngeal carcinoma that progressed after chemotherapy and programmed cell death protein 1 (PD-1) and its ligand (PD-L1) inhibitors have few treatment options and a poor prognosis. We therefore aimed to investigate the efficacy and safety of the bispecific antibody-drug conjugate izalontamab brengitecan (iza-bren) in heavily pretreated individuals with recurrent or metastatic nasopharyngeal carcinoma.
6. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.
作者: Zhiwei Chen.;Fang Yang.;Zhou Jiang.;Longhua Sun.;Lin Wu.;Zhengxiang Han.;Yun Fan.;Yanqiu Zhao.;Xingya Li.;Haipeng Xu.;Xiangjiao Meng.;Ying Liu.;Zhiye Zhang.;Hui Luo.;Xuelei Ma.;Xuezhen Ma.;Qin Shi.;Zhongmin Zhang.;Runxiang Yang.;Pingli Wang.;Pinhua Pan.;Xiaohong Ai.;Jie Li.;Xingxiang Pu.;Zhiwu Wang.;Jian Fang.;Ming He.;Yong He.;Shuliang Guo.;Juan Li.;Hongbiao Wang.;Junqiang Zhang.;Qian Chu.;Xuewen Liu.;Shenpeng Ying.;Hongcheng Wu.;Hongmei Sun.;Yinghua Ji.;Ming Zhou.;Chao Cao.;Kejing Tang.;Zhengguo Li.;Dairong Li.;Zhihong Zhang.;Jie Li.;Jianya Zhou.;Hongzhong Yang.;Yingying Du.;Hui Yang.;Jian Shi.;Hualin Chen.;Wenting Li.;Dongmei Lu.;Mingxiu Hu.;Zhongmin Maxwell Wang.;Baiyong Li.;Michelle Xia.;Shun Lu.
来源: Lancet. 2025年406卷10515期2078-2088页
Squamous non-small-cell lung cancer (NSCLC) is associated with worse clinical outcomes than non-squamous NSCLC, but treatment options are scarce. We aimed to evaluate the efficacy and safety of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as a first-line therapy for patients with advanced squamous NSCLC.
7. Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial.
作者: Charles Burdet.;Nadia Saïdani.;Céline Dupieux.;Adrien Lemaignen.;Etienne Canouï.;Laure Surgers.;Marc Olivier Vareil.;Agnès Lefort.;Raphaël Lepeule.;Nathan Peiffer-Smadja.;Alexandre Charmillon.;Vincent Le Moing.;David Boutoille.;Violaine Tolsma.;Sophie Abgrall.;Michel Wolff.;Pierre Tattevin.;Marina Esposito-Farèse.;François Vandenesch.;Xavier Duval.;Sarah Tubiana.;François-Xavier Lescure.; .
来源: Lancet. 2025年406卷10517期2349-2359页
Although widely used, cefazolin efficacy for the treatment of meticillin-susceptible Staphylococcus aureus (MSSA) bacteraemia has not thus far been investigated in a clinical trial. In this study, we aimed to compare the efficacy and safety of cefazolin with that of cloxacillin in patients with MSSA bacteraemia.
8. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
作者: Maria De Santis.;Joan Palou Redorta.;Hiroyuki Nishiyama.;Michał Krawczyński.;Artur Seyitkuliev.;Andrey Novikov.;Félix Guerrero-Ramos.;Ruslan Zukov.;Minoru Kato.;Takashi Kawahara.;Lieven Goeman.;Javier Puente.;Eva Hellmis.;Thomas Powles.;Piotr Radziszewski.;Kilian M Gust.;Paul Vasey.;Pierre Bigot.;Yves Fradet.;Jarmo Hunting.;Jon Armstrong.;Suliman Boulos.;Stephan Hois.;Neal D Shore.; .
来源: Lancet. 2025年406卷10516期2221-2234页
Patients with high-risk non-muscle-invasive bladder cancer (NMIBC) often have recurrence or progression after transurethral resection of bladder tumour (TURBT) and subsequent BCG therapy. We aimed to evaluate whether 1 year of durvalumab with BCG could improve outcomes versus BCG alone for these patients.
9. Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trial.
作者: Winfried Randerath.;Ludger Grote.;Kaj Stenlöf.;Ingo Fietze.;Julia Chevts.;Erik Buntinx.;Javier Albares.;Katrin Kuhn.;Corinna Hansen.;Andreas Völp.;Jan Hedner.; .
来源: Lancet. 2025年406卷10514期1983-1992页
Obstructive sleep apnoea (OSA) is highly prevalent but approved pharmacological treatment options are missing. Sultiame improves the ventilatory response and upper airway muscle activity by inhibiting carbonic anhydrase. This study aimed to prospectively assess the efficacy and safety of three dosages of sultiame in OSA.
10. Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.
作者: David J Lewis.;Mats Jerkeman.;Lexy Sorrell.;David Wright.;Ingrid Glimelius.;Christian B Poulsen.;Annika Pasanen.;Andrew Rawstron.;Karin F Wader.;Nick Morley.;Catherine Burton.;Andrew J Davies.;Ingemar Lagerlöf.;Surita Dalal.;Ruth De Tute.;Chris McNamara.;Nicola Crosbie.;Helle Erbs Toldbod.;Jeanette Sanders.;Victoria Allgar.;Sree Aroori.;Mark Warner.;Claire Scully.;Brian Wainman.;Jacob Haaber Christensen.;Jon Riise.;Kristina Sonnevi.;Mark J Bishton.;Toby A Eyre.;Simon Rule.; .
来源: Lancet. 2025年406卷10514期1953-1968页
Ibrutinib, a Bruton tyrosine kinase inhibitor, prolongs progression-free survival when added to immunochemotherapy as first line treatment. The ENRICH trial compared the chemotherapy-free combination of ibrutinib and the anti-CD20 antibody rituximab (ibrutinib-rituximab) with standard immunochemotherapy (R-CHOP [rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone] or bendamustine-rituximab) in patients 60 years and older with untreated mantle-cell lymphoma.
11. Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.
作者: Jeremy Chataway.;Thomas Williams.;James Blackstone.;Nevin John.;Marie Braisher.;Floriana De Angelis.;Alessia Bianchi.;Alberto Calvi.;Anisha Doshi.;Sean Apap Mangion.;Charles Wade.;Ekaterina Bordea.;Rachel Merry.;Gil Barton.;Dawn Lyle.;Elisabeth Jarman.;Don Mahad.;Abdullah Shehu.;Tarunya Arun.;Gavin McDonnell.;Ruth Geraldes.;Matthew Craner.;Charles Hillier.;Jeban Ganesalingam.;Leonora Fisniku.;Jeremy Hobart.;Cord Spilker.;Neil P Robertson.;Seema Kalra.;Stefano Pluchino.;Sreedharan Harikrishnan.;Miriam Mattoscio.;Timothy Harrower.;Carolyn Young.;Martin Lee.;Suresh Kumar Chhetri.;Fayyaz Ahmed.;David Rog.;Eli Silber.;Paul Gallagher.;Martin Duddy.;Agne Straukiene.;Richard Nicholas.;Claire Rice.;Susan Tebbs.;Annie Hawton.;Rachael Hunter.;Gavin Giovannoni.;Olga Ciccarelli.;Judy Beveridge.;Stuart Nixon.;Alan J Thompson.;John Greenwood.;Owen R Pearson.;Nikos Evangelou.;Basil Sharrack.;Ian Galea.;Emma Gray.;Sue Pavitt.;Siddharthan Chandran.;Helen L Ford.;Chris Frost.;Jennifer M Nicholas.; .
来源: Lancet. 2025年406卷10512期1611-1624页
Despite the success of immune modulation in the treatment of relapsing multiple sclerosis, disability progression is a major problem driven by multiple mechanisms. Comorbidities (eg, vascular risk) and ageing are thought to augment these neurodegenerative pathologies. In the phase 2b MS-STAT trial of simvastatin (80 mg) versus placebo in secondary progressive multiple sclerosis (SPMS), the adjusted difference in brain atrophy rate between groups was -0·254% per year: a 43% reduction. In this phase 3 MS-STAT2 trial, we aimed to assess the efficacy of simvastatin versus placebo in slowing the progression of disability in SPMS.
12. Budesonide-formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
作者: Lee Hatter.;Mark Holliday.;Karen Oldfield.;Ciléin Kearns.;Tasmin Barry.;Melissa Black.;Pepa Bruce.;Atalie Colman.;Emily Dickinson.;Allie Eathorne.;Matire Harwood.;Thomas Hills.;Rebekah Lamb.;Kyley Kerse.;Srinidhi Krishnamoorthy.;John Martindale.;Alex Semprini.;Nick Shortt.;David McNamara.;Catherine A Byrnes.;Stuart R Dalziel.;Andrew Bush.;Mark Weatherall.;Richard Beasley.; .
来源: Lancet. 2025年406卷10511期1473-1483页
Combination inhaled corticosteroid-formoterol reliever monotherapy reduces the rate of asthma attacks compared to short-acting β2-agonist (SABA) reliever monotherapy in adults. Its comparative efficacy in children has not been established.
13. A clinical decision tool including a decision tree, point-of-care testing of CRP, and safety-netting advice to guide antibiotic prescribing in acutely ill children in primary care in Belgium (ARON): a pragmatic, cluster-randomised, controlled trial.
作者: Jan Yvan Verbakel.;Ruben Burvenich.;Erinn D'hulster.;Liselore De Rop.;Ann Van den Bruel.;Sibyl Anthierens.;Samuel Coenen.;An De Sutter.;Stefan Heytens.;Louise Joly.;Marina Digregorio.;Annouschka Laenen.;Jeroen Luyten.;Tine De Burghgraeve.
来源: Lancet. 2025年406卷10512期1599-1610页
Antimicrobial resistance is a global health threat. Many children with acute illness in ambulatory care are unnecessarily prescribed antibiotics. We assessed the clinical effectiveness of a clinical decision tool for these children, including a validated decision tree, guided point-of-care C-reactive protein testing (POCT of CRP), and safety-netting advice.
14. Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study.
作者: David Kavanagh.;Andrew S Bomback.;Marina Vivarelli.;Carla M Nester.;Giuseppe Remuzzi.;Ming-Hui Zhao.;Edwin K S Wong.;Yaqin Wang.;Induja Krishnan.;Imelda Schuhmann.;Angelo J Trapani.;Nicholas J A Webb.;Matthias Meier.;Rubeen K Israni.;Richard J H Smith.; .
来源: Lancet. 2025年406卷10512期1587-1598页
C3 glomerulopathy is an ultra-rare, severe form of glomerulonephritis caused by overactivation of the alternative complement pathway. We aimed to assess efficacy and safety of iptacopan (LNP023), an oral, proximal complement inhibitor that targets factor B to selectively inhibit the alternative pathway of the complement cascade.
15. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
作者: Linda Stein Gold.;April W Armstrong.;Robert Bissonnette.;Nina Magnolo.;Ronald B Vender.;Michael Sebastian.;Maria Laura Galimberti.;Athanasios Tsianakas.;Marcelo Arnone.;Paul Wallace.;Margrit Simon.;Josep Riera-Monroig.;Sascha Gerdes.;Jill Waibel.;Alvaro Gonzalez-Cantero.;Beate Schwarz.;Yayoi Tada.;Michael Cecchini.;Benjamin Ehst.;Leon Kircik.;Lea Kephart.;Ofelia Reyes-Servin.;Bassey Effiom Edem.;Jennifer H Campbell.;Yaung-Kaung Shen.;Kellen Cresswell.;Shu Li.;Cynthia M C DeKlotz.;Fabio Nunes.;Kim A Papp.
来源: Lancet. 2025年406卷10510期1363-1374页
Monoclonal antibodies targeting interleukin-23 and interleukin-12 are efficacious in treating plaque psoriasis but must be delivered via intravenous or subcutaneous injection. Here, we aimed to evaluate the efficacy and safety of icotrokinra (JNJ-77242113), a targeted oral peptide that selectively binds the interleukin-23 receptor, compared with both placebo and deucravacitinib in adults with moderate-to-severe plaque psoriasis.
16. Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.
作者: Chantal Mathieu.;Julie Wych.;A Emile J Hendriks.;Lisa Van Ryckeghem.;Timothy Tree.;Piotr Chmura.;Christopher Möller.;Kristina Casteels.;Thomas Danne.;Felix Reschke.;Darja Šmigoc Schweiger.;Tadej Battelino.;Jesper Johannesen.;Birgit Rami-Merhar.;Thomas Pieber.;Christophe De Block.;Mark Evans.;Robert Hilbrands.;Emanuele Bosi.;Ruben H Willemsen.;Supriyo Basu.;Mari-Anne Pulkkinen.;Mikael Knip.;Miriam Cnop.;Almut Nitsche.;Anke M Schulte.;Elisabeth Niemöller.;Mark Peakman.;Charlotte Wilhelm-Benartzi.;David Gillespie.;Lut Overbergh.;Adrian P Mander.;M Loredana Marcovecchio.; .
来源: Lancet. 2025年406卷10510期1375-1388页
Type 1 diabetes remains an important health-care problem, with no disease-modifying therapies available in people with recent-onset, clinical type 1 diabetes. Adaptive trial designs, allowing faster evaluation of treatment modalities, remain underexplored in this stage of the disease. We aimed to identify the minimum effective dose of antithymocyte globulin (ATG) in people aged 5-25 years with recent-onset, clinical type 1 diabetes.
17. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.
作者: Tamara S Hannon.;Lily C Chao.;Margarita Barrientos-Pérez.;Karthik Chandrasekhar Pamidipati.;Laura Fernández Landó.;Clare J Lee.;Hiren Patel.;Brandon K Bergman.
来源: Lancet. 2025年406卷10511期1484-1496页
Current treatment options for youth-onset type 2 diabetes are limited and have demonstrated lower glycaemic efficacy than those for adult-onset type 2 diabetes. We aimed to assess the safety and efficacy of tirzepatide, a glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, compared with placebo in youth-onset type 2 diabetes.
18. Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.
作者: Subodh Verma.;Lawrence A Leiter.;Hwee Teoh.;G B John Mancini.;Adrian Quan.;Randi Elituv.;Meena Verma.;Elizabeth Misner.;Michael Szarek.;Kevin E Thorpe.;Tarit Saha.;Richard P Whitlock.;Bobby Yanagawa.;Béla Merkely.;Peter Jüni.;Michael J Koren.;Stephen J Nicholls.;Deepak L Bhatt.;C David Mazer.
来源: Lancet. 2025年406卷10509期1223-1234页
Saphenous vein graft (SVG) failure remains a substantial challenge after coronary artery bypass graft (CABG). LDL cholesterol (LDL-C) is a causal risk factor for atherosclerosis, but its role in SVG failure is not well established. We evaluated whether early initiation of intensive LDL-C lowering with evolocumab could reduce SVG failure.
19. Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1): a multicentre, participant-masked, registry-based, randomised controlled trial.
作者: Mårten Falkenberg.;Stefan James.;Manne Andersson.;Mattias Andersson.;Martin Delle.;Jan Engström.;Torbjörn Fransson.;Peter Gillgren.;Anna Hilbertson.;Tal M Hörer.;Eva Jacobsson.;Björn Kragsterman.;Johan Lindbäck.;Hans Lindgren.;Karin Ludwigs.;Stefan Mellander.;Olle Nelzén.;Robert Olin.;Birgitta Sigvant.;Per Skoog.;Joachim Starck.;Gustaf Tegler.;Knut Thorbjørnsen.;Maria Truedson.;Carl-Magnus Wahlgren.;Jonas Wallinder.;Andreas Öjersjö.;Joakim Nordanstig.; .
来源: Lancet. 2025年406卷10508期1103-1114页
Drug-coated devices are frequently used in coronary and peripheral interventions, but their effect on amputation risk in peripheral artery disease is unclear. We assessed whether drug-coated devices affect the rate of above-ankle amputation in patients with chronic limb-threatening ischaemia undergoing infrainguinal endovascular revascularisation.
20. Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2): a multicentre, participant-masked, registry-based, randomised controlled trial.
作者: Joakim Nordanstig.;Stefan James.;Manne Andersson.;Mattias Andersson.;Martin Delle.;Jan Engström.;Torbjörn Fransson.;Peter Gillgren.;Anna Hilbertson.;Tal M Hörer.;Eva Jacobsson.;Björn Kragsterman.;Johan Lindbäck.;Hans Lindgren.;Karin Ludwigs.;Stefan Mellander.;Olle Nelzén.;Robert Olin.;Birgitta Sigvant.;Per Skoog.;Joachim Starck.;Gustaf Tegler.;Knut Thorbjørnsen.;Maria Truedson.;Carl-Magnus Wahlgren.;Jonas Wallinder.;Andreas Öjersjö.;Mårten Falkenberg.; .
来源: Lancet. 2025年406卷10508期1115-1127页
Drug-coated devices are widely used to reduce restenosis after lower limb revascularisation in patients with peripheral artery disease, but their effect on patient-centred outcomes remains unclear. We assessed the effect of paclitaxel-coated devices on clinically important outcomes in patients with intermittent claudication undergoing infrainguinal endovascular revascularisation.
|